Universal Beteiligungs und Servicegesellschaft mbH Increases Stake in Intellia Therapeutics, Inc. $NTLA

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 74.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 113,438 shares of the company’s stock after acquiring an additional 48,438 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Intellia Therapeutics were worth $1,959,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 154.1% during the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares in the last quarter. Woodline Partners LP acquired a new stake in Intellia Therapeutics during the first quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after buying an additional 38,521 shares during the period. Cyndeo Wealth Partners LLC purchased a new position in Intellia Therapeutics in the second quarter valued at $101,000. Finally, CWM LLC raised its position in shares of Intellia Therapeutics by 22.9% in the second quarter. CWM LLC now owns 18,331 shares of the company’s stock worth $172,000 after acquiring an additional 3,419 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on NTLA shares. JPMorgan Chase & Co. restated an “underweight” rating and set a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. William Blair lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Guggenheim cut Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 27th. Chardan Capital decreased their target price on Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Robert W. Baird set a $7.00 price target on shares of Intellia Therapeutics in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics has a consensus rating of “Hold” and an average price target of $18.00.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $13.15 on Friday. The stock has a 50 day moving average price of $10.44 and a 200 day moving average price of $12.96. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.25. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -3.08 and a beta of 2.05.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter last year, the firm posted ($1.34) EPS. The firm’s revenue for the quarter was up 51.6% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. The trade was a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 53,051 shares of company stock worth $488,600. Insiders own 3.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.